This report builds upon WISIT’s previous preclinical success targeting aSyn in Parkinson’s Disease 27] which is due to begin phase I clinical study in early 2025 [47], demonstrating that the WISIT platform is not disease-specific, but has the potential for application to a wide variety of diseases, including pruritic dermatological disorders driven by IL-31. Here, IL31 is linked to Parkinson disease.